<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01048424</url>
  </required_header>
  <id_info>
    <org_study_id>SPIRIT001</org_study_id>
    <nct_id>NCT01048424</nct_id>
  </id_info>
  <brief_title>Slow Paced-Respiration Intervention to Reduce Incontinence Trial (SPIRIT)</brief_title>
  <acronym>SPIRIT</acronym>
  <official_title>Slow Paced-Respiration Intervention to Reduce Incontinence Trial (SPIRIT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Urgency incontinence is a common and burdensome problem in women. Current treatments for this
      condition, while effective, are associated with potentially disabling side effects and high
      rates of discontinuation. There is an urgent need for alternate treatments for urgency
      incontinence that are both clinically effective and well-tolerated by women in the community.

      RESPeRATE is a commercially available &quot;walkman-like&quot; device that measures chest/abdominal
      excursion during respiration using an elastic belt with a sensor placed around the torso over
      clothing. The device senses respiration and uses musical tones keyed to inhalation and
      exhalation to help the user slow respiration and prolong exhalation to a recommended goal of
      less than 10 breaths per minute. RESPeRATE is approved by the US Food and Drug Administration
      (FDA) for treatment of mild hypertension, and use of the device has also been shown to
      decrease self-reported anxiety and stress, oxygen consumption, and respiratory rate. Because
      anxiety and stress are strongly associated with urgency incontinence, and common behavioral
      strategies for managing incontinence emphasize relaxation and slow breathing at the time of
      an urgency episode, paced respiration may also be useful in treating urgency incontinence
      and/or decreasing its burden on quality of life.

      We propose to conduct a 6-week pilot randomized controlled trial of slow paced respiration
      using the RESPeRATE device among 30 women with urgency incontinence to assess the feasibility
      of recruiting and teaching women to use the RESPeRATE device as well as to gather preliminary
      data on the efficacy of slow paced respiration for treatment of urgency incontinence and
      related symptoms. Participants will complete a 7-day voiding diary and complete
      questionnaires to measure outcome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Urgency Urinary Incontinence Episodes Per Week</measure>
    <time_frame>baseline to 6 weeks</time_frame>
    <description>The number of incontinence episodes per week was calculated only over a 1-week period before the 6-week visit. There were no other interim outcomes assessment timepoints.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Any Urinary Incontinence Episodes Per Week</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>The number of incontinence episodes per week was calculated only over a 1-week period before the 6-week visit. There were no other interim outcomes assessment timepoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Daytime Voiding Frequency.</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>The number of incontinence episodes per week was calculated only over a 1-week period before the 6-week visit. There were no other interim outcomes assessment timepoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Overactive Bladder Symptoms</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>The Overactive Bladder Questionnaire (OAB-Q). 0- to 100-point scale. Higher scores on the OAB-Q indicate greater bothersomeness and impact of overactive bladder symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Anxiety Symptoms</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>Hospital Anxiety and Depression Scale. Anxiety Subscale range from 0 to 21, with scores of less than 8 indicative of absence of anxiety symptoms, 8 or above suggesting anxiety symptoms, and 12 or above suggesting generalized anxiety disorder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Depression Symptoms</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>Beck Depression Inventory. Range of 0-63 (0-9 normal; 10-16 mild; 17-29 moderate; 30-63 severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Perceived Stress</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>Cohen Perceived Stress Scale. Scores are scaled from 0 to 40, with higher scores indicated greater perceived stress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sleep Quality</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>The Pittsburgh Sleep Quality Index. A global sleep quality score derived from the PSQI can be used to index overall quality of sleep over the prior one-week period. Global sleep quality scores are continuous (range 0-21), with high scores reflecting poor sleep quality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Incontinence- or Bladder-specific Quality of Life</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>Incontinence Impact Questionnaire. Scores on the overall IIQ range from 0 to 400, with higher scores indicating greater overall impact on quality of life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Urinary Incontinence, Urge</condition>
  <arm_group>
    <arm_group_label>Paced respiration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be instructed to practice slow-paced respiration for 15 minutes a day using the RESPeRATE device, and will also be given a Urinary Incontinence pamphlet containing general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be given a Urinary Incontinence pamphlet including general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RESPeRATE</intervention_name>
    <description>RESPeRATE is a commercially available, &quot;walkman-like&quot; device manufactured by Intercure, Ltd. that measures chest/abdominal excursion during respiration using an elastic belt with a sensor placed around the torso over clothing. The device senses respiration and uses musical tones keyed to inhalation and exhalation to help the user slow respiration and prolong exhalation to a recommended goal of less than 10 breaths per minute. RESPeRATE is approved by the FDA for treatment of mild hypertension and has also been shown to decrease self-reported anxiety and stress, oxygen consumption, and respiratory rate.</description>
    <arm_group_label>Paced respiration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Urinary Incontinence Pamphlet</intervention_name>
    <description>The urinary incontinence pamphlet will provide information about classification, pathophysiology, and management of urinary incontinence, including management strategies such as timed urination and pelvic muscle exercises.</description>
    <arm_group_label>Paced respiration</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 18 years or older who report urinary incontinence for greater than or equal
             to 3 months prior to screening

          -  Report that the majority of their incontinence episodes are associated with a
             sensation of urgency

          -  Record at least 7 urgency incontinence episodes per week on a screening 7-day voiding
             diary

          -  Able to walk to the toilet and use the toilet by themselves without difficulty

          -  Willing to refrain from initiating treatments that may affect their voiding pattern
             during the trial period

          -  Capable of understanding study procedures and giving informed consent

        Exclusion Criteria:

          -  Current use of medical therapy for incontinence or use within the previous month
             (participants may be able to stop use of therapy and re-present for study)

          -  Currently pregnant, gave birth within the past 3 months, or planning pregnancy during
             the study period (approximately 2 months)

          -  Current urinary tract infection (screening dipstick urinalysis with leukocyte estrace,
             nitrites or blood) or a history or 4 or more urinary tract infections in the preceding
             year

          -  Report history of neurologic conditions such as stroke, multiple sclerosis, spinal
             cord injury, Parkinson's disease

          -  Report history of interstitial cystitis, fistula or hole in bladder or rectum, or
             birth defect leading to urine leakage

          -  Report history of pulmonary disease including emphysema, chronic bronchitis, or
             chronic obstructive pulmonary disease

          -  Measured resting blood pressure (average of 2 measures) less than 100/60 at screening
             or baseline examination

          -  Report any history of prior anti-incontinence or urethral surgery, pelvic cancer, or
             pelvic irradiation for any reason

          -  Report use of bladder botox, electrostimulation, bladder training, or pelvic floor
             exercise training (with certified practitioners) in the past 3 months

          -  Report other surgery to the pelvis (hysterectomy, oophorectomy, vaginal surgery,
             bladder surgery, colon surgery) during the past 3 months

          -  Report conditions that, in the judgment of the clinical center Principal Investigator,
             render potential participants unlikely to follow the protocol, including plans to
             move, substance abuse, significant psychiatric problems, or dementia

          -  Participation in another research study that involves investigational drugs or devices
             that could potentially confound the results of this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alison Huang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF-Mt. Zion Women's Health Clinical Research Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2010</study_first_submitted>
  <study_first_submitted_qc>January 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2010</study_first_posted>
  <results_first_submitted>May 22, 2013</results_first_submitted>
  <results_first_submitted_qc>October 29, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 21, 2013</results_first_posted>
  <last_update_submitted>October 29, 2013</last_update_submitted>
  <last_update_submitted_qc>October 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Alison Huang</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Urinary incontinence</keyword>
  <keyword>Paced respiration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Paced Respiration</title>
          <description>Participants will be instructed to practice slow-paced respiration for 15 minutes a day using the RESPeRATE device, and will also be given a pamphlet containing general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.</description>
        </group>
        <group group_id="P2">
          <title>Usual Care</title>
          <description>Participants will be given a pamphlet including general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Paced Respiration</title>
          <description>Participants will be instructed to practice slow-paced respiration for 15 minutes a day using the RESPeRATE device, and will also be given a pamphlet containing general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.</description>
        </group>
        <group group_id="B2">
          <title>Usual Care</title>
          <description>Participants will be given a pamphlet including general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.7" spread="10.9"/>
                    <measurement group_id="B2" value="54.73" spread="16.8"/>
                    <measurement group_id="B3" value="56" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Urgency Urinary Incontinence Episodes Per Week</title>
        <description>The number of incontinence episodes per week was calculated only over a 1-week period before the 6-week visit. There were no other interim outcomes assessment timepoints.</description>
        <time_frame>baseline to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paced Respiration</title>
            <description>Participants will be instructed to practice slow-paced respiration for 15 minutes a day using the RESPeRATE device, and will also be given a pamphlet containing general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants will be given a pamphlet including general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Urgency Urinary Incontinence Episodes Per Week</title>
          <description>The number of incontinence episodes per week was calculated only over a 1-week period before the 6-week visit. There were no other interim outcomes assessment timepoints.</description>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33" spread="40"/>
                    <measurement group_id="O2" value="-6" spread="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Any Urinary Incontinence Episodes Per Week</title>
        <description>The number of incontinence episodes per week was calculated only over a 1-week period before the 6-week visit. There were no other interim outcomes assessment timepoints.</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paced Respiration</title>
            <description>Participants will be instructed to practice slow-paced respiration for 15 minutes a day using the RESPeRATE device, and will also be given a pamphlet containing general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Participants will be given a pamphlet including general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Any Urinary Incontinence Episodes Per Week</title>
          <description>The number of incontinence episodes per week was calculated only over a 1-week period before the 6-week visit. There were no other interim outcomes assessment timepoints.</description>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18" spread="40"/>
                    <measurement group_id="O2" value="-2" spread="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Daytime Voiding Frequency.</title>
        <description>The number of incontinence episodes per week was calculated only over a 1-week period before the 6-week visit. There were no other interim outcomes assessment timepoints.</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paced Respiration</title>
            <description>Participants will be instructed to practice slow-paced respiration for 15 minutes a day using the RESPeRATE device, and will also be given a pamphlet containing general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Participants will be given a pamphlet including general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Daytime Voiding Frequency.</title>
          <description>The number of incontinence episodes per week was calculated only over a 1-week period before the 6-week visit. There were no other interim outcomes assessment timepoints.</description>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9" spread="20"/>
                    <measurement group_id="O2" value="3" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Overactive Bladder Symptoms</title>
        <description>The Overactive Bladder Questionnaire (OAB-Q). 0- to 100-point scale. Higher scores on the OAB-Q indicate greater bothersomeness and impact of overactive bladder symptoms.</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paced Respiration</title>
            <description>Participants will be instructed to practice slow-paced respiration for 15 minutes a day using the RESPeRATE device, and will also be given a pamphlet containing general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Participants will be given a pamphlet including general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Overactive Bladder Symptoms</title>
          <description>The Overactive Bladder Questionnaire (OAB-Q). 0- to 100-point scale. Higher scores on the OAB-Q indicate greater bothersomeness and impact of overactive bladder symptoms.</description>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.63" spread="0.9"/>
                    <measurement group_id="O2" value="-.44" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Anxiety Symptoms</title>
        <description>Hospital Anxiety and Depression Scale. Anxiety Subscale range from 0 to 21, with scores of less than 8 indicative of absence of anxiety symptoms, 8 or above suggesting anxiety symptoms, and 12 or above suggesting generalized anxiety disorder.</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paced Respiration</title>
            <description>Participants will be instructed to practice slow-paced respiration for 15 minutes a day using the RESPeRATE device, and will also be given a pamphlet containing general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Participants will be given a pamphlet including general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Anxiety Symptoms</title>
          <description>Hospital Anxiety and Depression Scale. Anxiety Subscale range from 0 to 21, with scores of less than 8 indicative of absence of anxiety symptoms, 8 or above suggesting anxiety symptoms, and 12 or above suggesting generalized anxiety disorder.</description>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.78" spread="2.4"/>
                    <measurement group_id="O2" value="-.57" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Depression Symptoms</title>
        <description>Beck Depression Inventory. Range of 0-63 (0-9 normal; 10-16 mild; 17-29 moderate; 30-63 severe).</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paced Respiration</title>
            <description>Participants will be instructed to practice slow-paced respiration for 15 minutes a day using the RESPeRATE device, and will also be given a pamphlet containing general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Participants will be given a pamphlet including general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Depression Symptoms</title>
          <description>Beck Depression Inventory. Range of 0-63 (0-9 normal; 10-16 mild; 17-29 moderate; 30-63 severe).</description>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.67" spread="3.7"/>
                    <measurement group_id="O2" value="2.25" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Perceived Stress</title>
        <description>Cohen Perceived Stress Scale. Scores are scaled from 0 to 40, with higher scores indicated greater perceived stress.</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paced Respiration</title>
            <description>Participants will be instructed to practice slow-paced respiration for 15 minutes a day using the RESPeRATE device, and will also be given a pamphlet containing general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Participants will be given a pamphlet including general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Perceived Stress</title>
          <description>Cohen Perceived Stress Scale. Scores are scaled from 0 to 40, with higher scores indicated greater perceived stress.</description>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.13" spread="3.5"/>
                    <measurement group_id="O2" value="4.13" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sleep Quality</title>
        <description>The Pittsburgh Sleep Quality Index. A global sleep quality score derived from the PSQI can be used to index overall quality of sleep over the prior one-week period. Global sleep quality scores are continuous (range 0-21), with high scores reflecting poor sleep quality.</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paced Respiration</title>
            <description>Participants will be instructed to practice slow-paced respiration for 15 minutes a day using the RESPeRATE device, and will also be given a pamphlet containing general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Participants will be given a pamphlet including general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sleep Quality</title>
          <description>The Pittsburgh Sleep Quality Index. A global sleep quality score derived from the PSQI can be used to index overall quality of sleep over the prior one-week period. Global sleep quality scores are continuous (range 0-21), with high scores reflecting poor sleep quality.</description>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.43" spread="2.0"/>
                    <measurement group_id="O2" value="-.38" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Incontinence- or Bladder-specific Quality of Life</title>
        <description>Incontinence Impact Questionnaire. Scores on the overall IIQ range from 0 to 400, with higher scores indicating greater overall impact on quality of life.</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paced Respiration</title>
            <description>Participants will be instructed to practice slow-paced respiration for 15 minutes a day using the RESPeRATE device, and will also be given a pamphlet containing general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Participants will be given a pamphlet including general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Incontinence- or Bladder-specific Quality of Life</title>
          <description>Incontinence Impact Questionnaire. Scores on the overall IIQ range from 0 to 400, with higher scores indicating greater overall impact on quality of life.</description>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.15" spread="0.5"/>
                    <measurement group_id="O2" value="-.06" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Paced Respiration</title>
          <description>Participants will be instructed to practice slow-paced respiration for 15 minutes a day using the RESPeRATE device, and will also be given a pamphlet containing general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.</description>
        </group>
        <group group_id="E2">
          <title>Usual Care</title>
          <description>Participants will be given a pamphlet including general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Fatigue Issues</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Swelling of both feet</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Rapid Heart Beat Issues</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lower Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache Issues</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Light-Headedness Issues</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alison Huang, MD</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>415-353-9751</phone>
      <email>ahuang@medicine.ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

